Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 14:2018:6192187.
doi: 10.1155/2018/6192187. eCollection 2018.

Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

Vladimir Jurišić  1 , Jasmina Obradovic  2 , Sonja Pavlović  3 , Nataša Djordjevic  1
Affiliations
Review

Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

Vladimir Jurišić et al. Anal Cell Pathol (Amst). .

Abstract

Recently, epidermal growth factor receptor (EGFR) was a key molecule in investigation of lung cancer, and it was a target for a new therapeutic strategy, based on molecular analyses. In this review, we have summarized some issues considering the role of EGFR in lung cancer, its coding gene, and its promoter gene polymorphisms (SNPs) -216G/T and -191C/A in non-small-cell lung cancer (NSCLC). The position of the SNPs indicates their significant role in EGFR regulation. The accumulation of knowledge regarding SNPs lately suggests their significant and important role in the onset of carcinogenesis, the prediction of the onset of metastases, the response to therapy with TKI inhibitors, and the onset of toxic effects of the applied therapy. Based on this, we suggest further studies of the relationship of clinical significance to SNPs in patients with lung tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
EGFR gene location on chromosome 7 and functional characteristics of two SNPs -191C/A and -216G/T placed in the EGFR promoter region.
See this image and copyright information in PMC

References

    1. Witschi H. A short history of lung cancer. Toxicological Sciences. 2001;64(1):4–6. doi: 10.1093/toxsci/64.1.4. - DOI - PubMed
    1. Ettinger D. S., Akerley W., Borghaei H., et al. Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network. 2012;10(10):1236–1271. doi: 10.6004/jnccn.2012.0130. - DOI - PubMed
    1. Esposito L., Conti D., Ailavajhala R., Khalil N., Giordano A. Lung cancer: are we up to the challenge? Current Genomics. 2010;11(7):513–518. doi: 10.2174/138920210793175903. - DOI - PMC - PubMed
    1. Nichols L., Saunders R., Knollmann F. D. Causes of death of patients with lung cancer. Archives of Pathology & Laboratory Medicine. 2012;136(12):1552–1557. doi: 10.5858/arpa.2011-0521-OA. - DOI - PubMed
    1. Mu X., Zhang Y., Qu X., et al. Ubiquitin ligase Cbl-b is involved in Icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. BioMed Research International. 2013;2013:8. doi: 10.1155/2013/726375.726375 - DOI - PMC - PubMed

MeSH terms